Tonix Pharmaceuticals (TNXP) stock gains as the company posts peer-reviewed data for pain drug TNX-102 and new data for mpox ...

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) saw its stock rise 2% after unveiling new preclinical findings for its ...

TNX-801 is up to 100,000-fold less virulent than live smallpox vaccine strains and a single dose provides robust immunogenicity and protection against mpox and rabbitpox (more than one year) in ...

Tonix Pharmaceuticals (NASDAQ: TNXP) , a fully integrated biopharmaceutical company, announced that Dr. Sina Bavari, Executive Vice President of Infe ...

Single dose vaccination with TNX-801 protects animals from a lethal challenge with monkeypox, the causative agent of mpox TNX ...

Market is projected to grow at a CAGR of 5% through 2029, fueled by rising R&D costs, declining pharmaceutical sales, growing ...

Eating Disorder Treatment Market 2025-2029" has been added to ResearchAndMarkets.com's offering. The binge-eating disorder treatment market is set to expand significantly, with an anticipated growth ...

Tonix Pharmaceuticals (NASDAQ: TNXP) , a fully integrated biotech company, announced its inclusion in the Russell 3000® and Russell 2000® Indexes fol ...

Tonix Pharmaceuticals (NASDAQ:TNXP) announced on Monday an addition to the broad-market Russell 3000 Index and an automatic inclusion in the small-cap Russell 2000 Index. Shares were +0.32% pre-market ...

Noble Financial analyst Robert LeBoyer reiterated a Buy rating on GeoVax Labs (GOVX – Research Report) today and set a price target of $10.00. The company’s shares opened toda ...

Detailed price information for Tonix Pharm Holdings (TNXP-Q) from The Globe and Mail including charting and trades.

CHATHAM, N.J., June 10, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biotechnology company with marketed products and a ...